ArticleCell reports2019
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 99 citations in OpenAlex.
- Oncostatin M as a Multifunctional Regulator of Breast Cancer Progression: Current Insights and Future Therapeutic Avenues.IUBMB life · 2026Review
- Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer.Nature communications · 2026Article
- A bibliometric analysis of trends and hotspots in Oncostatin M.Discover oncology · 2026Article
- Impact ofOncology research · 2026Article
- Activated protein C promotes human lung cancer progression through the release of tumor extracellular vesicles and transfer of microRNA-200a.Cell death & disease · 2025Article
- Secreted Frizzled-related proteins in animal development.Histochemistry and cell biology · 2025Review
- RNAa: Mechanisms, therapeutic potential, and clinical progress.Molecular therapy. Nucleic acids · 2025Review
- Multifunctional Nanomaterials: Recent Advancements in Cancer Therapeutics and Vaccines.Indian journal of microbiology · 2025Article
- OSMR induces M2 polarization of glioblastoma associated macrophages through JAK/STAT3 signaling pathway.Frontiers in oncology · 2025Article
- miRNA-driven sensitization of breast cancer cells to Doxorubicin treatment following exposure to low dose of Zinc Oxide nanoparticles.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- USP26 Combats Age-Related Declines in Self-Renewal and Multipotent Differentiation of BMSC by Maintaining Mitochondrial Homeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Activation of the osteoblastic HIF-1α pathway partially alleviates the symptoms of STZ-induced type 1 diabetes mellitus via RegIIIγ.Experimental & molecular medicine · 2024Article
- Blocking Oncostatin M receptor abrogates STAT3 mediated integrin signaling and overcomes chemoresistance in ovarian cancer.NPJ precision oncology · 2024Article
- IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma.Haematologica · 2023Article
- Extracellular Vesicles in Triple-Negative Breast Cancer: Immune Regulation, Biomarkers, and Immunotherapeutic Potential.Cancers · 2023Review
- A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.Journal of cancer research and clinical oncology · 2023Article
- DNA repair pathways in breast cancer: from mechanisms to clinical applications.Breast cancer research and treatment · 2023Review
- Review
- Integrative competing endogenous RNA network analyses identify novel lncRNA and genes implicated in metastatic breast cancer.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 5 institutions in 2 countries.
Deepak ParasharDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Anjali GeethadeviDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Miriam Ragle AureDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway.
Jyotsna MishraDepartment of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Jasmine GeorgeDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Changliang ChenDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Manoj K MishraDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Andliena TahiriDivision of Medicine, Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.
Wei ZhaoDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Bindu NairDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Yiling LuDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Lingegowda S MangalaDepartment of Gynecology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Amadou K S CamaraDepartment of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Mingyu LiangDepartment of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Janet S RaderDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Ramani RamchandranDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Ming YouMedical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Anil K SoodDepartment of Gynecology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Vessela N KristensenDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway; Division of Medicine, Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway.
Gordon B MillsDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Sunila PradeepDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Pradeep Chaluvally-RaghavanDepartment of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: pchaluvally@mcw.edu.
Medical College of Wisconsin · USThe University of Texas MD Anderson Cancer Center · USMedical College of Wisconsin Cancer CenterAkershus University Hospital · NOOslo University Hospital · NO
Funding
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MTUMOR SUPPRESSOR GENES IN BREAST CANCER DEVELOPMENTP50CA058183 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI OSBORNE, C KENT · 1992 to 2012
$30.9MU.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9MHarnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0MIntegrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerU01CA217842 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DENEEN, BENJAMIN, MILLS, GORDON B. · 2017 to 2021
$3.6MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2MTargeting DUSP-5 to Treat Vascular AnomaliesR01HL112639 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI RAMCHANDRAN, RAMANI · 2012 to 2016
$2.6MThe Role of Aberrant Splicing of EVl1 in Ovarian Cancer PathophysiologyR01CA123219 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MILLS, GORDON B., NANJUNDAN, MEERA · 2008 to 2012
$2.2MGenome-Wide Association Studies of Inherited Predisposition to Lung CancerR01CA134682 · NCI · WASHINGTON UNIVERSITY · PI LIU, PENGYUAN, YOU, MING · 2009 to 2013
$2.2MCystathionine beta synthase (CBS) and angiogenesisR01HL120585 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI BHATTACHARYA, RESHAM, MUKHERJEE, PRIYABRATA · 2013 to 2017
$2.1MDelta like-4 long non-coding RNA function in angiogenesis and vascular anomaliesR01HL123338 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI RAMCHANDRAN, RAMANI · 2015 to 2018
$1.8MNCATS NIH HHS UH3 TR000943NCI NIH HHS P50 CA058183NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA123219NCI NIH HHS R01 CA134682NCI NIH HHS R01 CA229907NCI NIH HHS R35 CA209904NCI NIH HHS U01 CA217842NHLBI NIH HHS R01 HL112639NHLBI NIH HHS R01 HL120585NHLBI NIH HHS R01 HL123338
Abstract
Genomic amplification of 3q26.2 locus leads to the increased expression of microRNA 551b-3p (miR551b-3p) in triple-negative breast cancer (TNBC). Our results demonstrate that miR551b-3p translocates to the nucleus with the aid of importin-8 (IPO8) and activates STAT3 transcription. As a consequence, miR551b upregulates the expression of oncostatin M receptor (OSMR) and interleukin-31 receptor-α (IL-31RA) as well as their ligands OSM and IL-31 through STAT3 transcription. We defined this set of genes induced by miR551b-3p as the "oncostatin signaling module," which provides oncogenic addictions in cancer cells. Notably, OSM is highly expressed in TNBC, and the elevated expression of OSM associates with poor outcome in estrogen-receptor-negative breast cancer patients. Conversely, targeting miR551b with anti-miR551b-3p reduced the expression of the OSM signaling module and reduced tumor growth, as well as migration and invasion of breast cancer cells.
Indexed as
Disease ProgressionSignal TransductionAnimalsbeta KaryopherinsCarcinogenesisCell Line, TumorCell MovementCell NucleusCell ProliferationGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMice, NudeMicroRNAsMolecular Targeted TherapyNeoplasm Invasivenessbeta KaryopherinsIPO8 protein, humanMicroRNAsMIRN551B microRNA, humanOncostatin MSTAT3 protein, humanSTAT3 Transcription FactorIPO8miR551bmiRNA-therapyoncostatinOSMRRNAiSTAT3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.